A majority of US Food and Drug Administration vaccine advisors cautioned against closing off the emergency use authorization pathway for COVID-19 vaccines in children over concerns that the pandemic’s trajectory in the US may again get worse, even as they also encouraged FDA to push sponsors for larger pre-authorization pediatric studies.
The comments from the Vaccines and Related Biological Products Advisory Committee on 10 June could help reassure FDA of the...







